ArticleTherapeutic advances in endocrinology and metabolism2023

Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment.

Khary Edwards et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.